Objectives To investigate short-term prognosis and prognostic factors for connective tissue disease-associated pneumocystis pneumonia (CTD-PCP) using the Japanese nationwide diagnosis procedure ...

Jih-Jin Tsai, Li-Teh Liu, Chun-Hong Chen, et al. COVID-19 outcomes in patients with rheumatoid arthritis with biologic or targeted synthetic DMARDs. RMD Open 2023;9:e003038. This article has been ...

Laura Cuesta-López, Iván Arias-de la Rosa, Jesús Eduardo Martín-Salazar, Antonio Manuel Barranco, Lourdes Ladehesa-Pineda, Miriam Ruiz-Ponce, María Ángeles Puche Larrubia, Carlos Pérez-Sánchez, Pedro ...

Patients with psoriatic arthritis (PsA) have a higher prevalence of diabetes mellitus (DM) compared to the general population, and PsA activity is associated with a higher risk of developing DM.1 2 ...

Mader R, Verlaan JJ, Eshed I, et al. Diffuse idiopathic skeletal hyperostosis (DISH): where we are now and where to go next. RMD Open 2017;3:e000472.

van Straalen JW, Akay G, Kouwenberg CV, et al. Methotrexate therapy associated with a reduced rate of new-onset uveitis in patients with biological-naïve juvenile idiopathic arthritis. RMD Open 2023;9 ...

In this article, the polymyalgia rheumatica (PMR) cohort inadvertently included controls from a previous analysis. Eliminating those controls reduced the sample size of the PMR cohort from 610 to 308.

Objectives The window of opportunity (WOO) hypothesis suggests a limited time frame to stop rheumatoid arthritis (RA). We hypothesised that a WOO could either be represented by a hyperbolic (‘curved’) ...

Pina Vegas L, Penso L, Sbidian E, et al. Influence of sex on the persistence of different classes of targeted therapies for psoriatic arthritis: a cohort study of 14 778 patients from the French ...

Arevalo Salaet M, López-Medina C, Moreno M, et al. Association between HLA-B27 and peripheral spondyloarthritis phenotype: results from the ASAS perSpA study. RMD Open 2022;8:e002696. Doi: ...

To cite: Wang J, Bao C, Dai Q, et al. Efficacy and safety of jaktinib hydrochloride tablets in active axial spondyloarthritis: a multicentre, randomised, double-blind, placebo-controlled phase II ...